Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

tions necessary to support the extension of expiration dating for urokinase inventory to between July and September of 2009. The Company submitted for and the FDA approved the release of three lots of urokinase during the first quarter of 2008 under the new Kinlytic trade name. The Company believes this labeled inventory will be sufficient to meet market demand through September 2009. ImaRx intends to continue its stability program to evaluate the potential for further expiration extensions beyond September 2009 for unlabeled vials of urokinase inventory.

Bradford A. Zakes stated, "The extension of the expiration dating and FDA approval of our recent requests for lot release represent a significant accomplishment for ImaRx, by allowing us to generate additional value from the continued sale of our urokinase inventory well into 2009. We remain confident that the stability profile of our urokinase inventory will enable us to achieve future expiration date extensions as we market the balance of our existing unlabeled vials of urokinase."

In January 2008 ImaRx signed a Letter of Intent with Microbix Biosystems Inc. (TSE: MBX) to manufacture and continue selling urokinase beyond the existing inventory. Closing of the transaction is dependent upon the satisfactory completion of due diligence and Microbix securing adequate financing to transfer the manufacturing process. A new supply of urokinase would allow ImaRx to continue to serve its current customers. It also would provide the opportunity to expand sales to additional vascular physicians and acute care institutions and to explore clinical development of urokinase for additional vascular indications.

In connection with the urokinase acquisition in April 2006, the Company issued a $15.0 million non-recourse promissory note to Abbott that matures on March 31, 2008. The outstanding balance of the note plus accrued interest, net of funds in escrow, is $10.8 million. The Company has reached a tentative
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:4/20/2014)... gift of germsgerms that help to kick-start the ... off infection, may paradoxically interrupt a newborn,s own ... to dangerous pathogens. , A new animal ... of Philadelphia (CHOP) sheds light on immunology in ... crucial role in fostering the rapid production of ...
(Date:4/18/2014)... X-ray crystallography and nuclear magnetic resonance imaging (NMR) to ... but such efforts have long been hampered by the ... molecule and often in ordered and crystalized form to ... peer into the structure of most molecules. , Harvard ... thing of the past. , A team of ...
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... Ill. (November 7, 2013) Chicago Botanic Garden researchers ... from the National Science Foundation to study the way ... to reproduce and survive. The floral scent may also ... role in the evolution and diversification of plant species. ...
... research on pond snails has revealed that high levels of ... Exeter and the University of Calgary trained snails and found ... were unable remember what they had learned. Previous research ... This study, published in the journal PLOS ONE , ...
... 6, 2013: In an article appearing in ... physician-researcher from the Touro College of Osteopathic Medicine has called ... a growth protein that could help predict an infant,s propensity ... findings in prior published studies, Touro researcher Gary Steinman, MD, ...
Cached Biology News:NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 2NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 3NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 4NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 5Stress makes snails forgetful 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 3